Transparency Guideline and the Sunshine Act Anti-Bribery/Anti-Corruption Initiatives Astellas conducts basic medical and pharmaceutical  research and clinical development of new drugs in collabo- ration with physicians, researchers, universities, and other  research and medical institutions in bringing innovative  medicines to patients worldwide. It is therefore important to  reassure stakeholders that the business activities of pharma- ceutical companies are founded in a high sense of ethics and  are intended to contribute to the advancement of medicine  and pharmacology. To this end, pharmaceutical and medical  device companies are required to provide information on their  payments to physicians and medical institutions. In Japan,  this disclosure is stipulated by the guideline of the Japan  Pharmaceutical Manufacturers Association (Transparency  Guideline), while in the U.S. it is set out in the Sunshine Act.  There are also similar laws and regulations in other countries.  Following these laws and guidelines, Astellas has established  a structure for collecting and organizing this information  swiftly and appropriately. Having done so, we then disclose  it publicly, report it to the authorities, or take other steps as  required in a timely and appropriate manner. Globally, countries have enacted laws and other measures  to target corruption and bribery. In some countries, new  stricter laws have been implemented. For example, authorities  in both the U.S. and the U.K. have increased enforcement  efforts regarding bribery of foreign government officials.  Anti-corruption is one of the ten principles of the United  Nations Global Compact, to which Astellas is a signatory. Against this backdrop, Astellas has strengthened its  process to prevent bribery and other forms of corruption.  Specific steps include establishing Global Anti-Bribery and  Anti-Corruption Policy, which elaborates on the rules and  principles designed to prevent bribery and corruption set  forth in the Astellas Global Code of Conduct. We also have  enhanced regional anti-bribery and anti-corruption policies  and procedures, and enhanced third party due diligence  guidelines. Additionally, we are conducting ongoing global  training which includes continued training for chief compli- ance officers at our bases in Japan, Asia/Oceania, EMEA  and the Americas, as well as enhanced global and regional  training to our employees. Each of these measures has  effectively strengthened awareness of global anti-bribery and  anti-corruption regulations. Astellas Global Compliance System Regional Compliance Officer (RCO) Compliance Committee Japan Asia/Oceania President and CEO Chief Compliance Officer (CCO) Global Compliance Committee Regional Compliance Officer (RCO) Compliance Committee U.S. Canada Brazil Regional Compliance Officer (RCO) Compliance Committee Europe Japan/Asia/Oceania Americas (North America, Central America and South America) EMEA (Europe, the Middle East and Africa) Middle East Africa 72 Astellas Pharma Inc.  _ Annual Report 2014